With 800-plus pharma, biotech and med-tech companies in the state, Telangana has a combined industry value of $50 billion. The state boasts of one of the largest life sciences sectors in Asia, which accounts for 35-40% of the national pharma production
The Telangana government is looking to leverage the life sciences and pharmaceutical sector to create a $100 billion industry in the coming decade. It plans to do so with initiatives such as the upcoming Hyderabad Pharma City–a 19,000 acre area catering to set up a value chain pharma industry, Genome Valley 2.0, a medical devices park, and the Biological Scale-up manufacturing facility (B-Hub).
With 800 plus pharma, biotech and medical technology companies in the state, Telangana already has a combined industry value of $50 billion. The state currently boasts of having one of the largest life sciences sector in Asia, accounting for 35-40% of the national pharma production. The Genome Valley near Hyderabad, one of Asia’s premium biotech and research and development hubs, is a case in point.
“Today, Hyderabad has emerged as the destination of choice for life sciences companies of all sizes given the extraordinary STEM (science, technology, engineering and management) talent pool, vibrant life sciences and technology ecosystem, presence of premier research institutes, availability of ready-to-occupy laboratory space and indeed, proactive government policies,” said Shakthi Nagappan, director, Life Sciences, government of Telangana.
According to data provided by the state government, 19 companies have already signed up and are in the process of setting up shop in the Telangana Medical Devices Park. It is likely to house Asia’s largest stent manufacturing facility, which is being set up by Sahajanand Medical Technologies. The government’s upcoming Pharma City project also aims to create the world’s largest integrated ecosystem in a 19,000-acre space, which will cater to create a complete value chain for the pharmaceutical industry.